Date:8/26/2011

ertainties include the effect of economic conditions, including the strength of any recovery from the global recession; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; changes in third-party reimbursement levels; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; currency exchange rates and tax rates; the effect of adverse publicity;; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Spencer Sias (650) 424-5782
spencer.sias@varian.com

'/>"/>

SOURCE Varian Medical Systems Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Varian Medical Systems Schedules Investor Meeting at ASTRO in Miami Beach, FL
2. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
3. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
4. David J. Illingworth Appointed to Board of Directors for Varian Medical Systems
5. South Florida Radiation Oncology on the Forefront of Cancer Treatment with the TrueBeam™ Radiotherapy System from Varian Medical Systems
6. Varian Medical Systems to Offer CIVCO Medical Solutions Body Pro-Lok™ for SBRT
7. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011
8. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
11. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment